Prevalence of Amyloid-Related Imaging Abnormalities in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Findings from Ongoing Clinical Trials of Oral Anti-Amyloid Agent ALZ-801 (Valiltramiprosate) (P5-6.003)
Susan Abushakra(Framingham State University), Martin Tolar(Alzheimer's Association), Philip Scheltens(Amsterdam University Medical Centers), Anton P. Porsteinsson(University of Rochester), Joyce Suhy(BioClinica (United States)), Marwan Sabbagh(Newcastle Hospitals - Campus for Ageing and Vitality), David Watson(Alzheimer’s Disease Neuroimaging Initiative), Rosalind Mandelbaum, Jerome Barakos(Sutter Health), John D. Hey, Patrick Kesslak, Aidan Power, Earvin Liang, Emer MacSweeney(Cambridge Cognition (United Kingdom))
Cited by 3
Related Papers
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|18.9k
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k